Ragnar Study Evidences Efficacy And Safety Of Erdafitinib In Patients With Advanced Fgfr+ Malign...

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malign...

THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations

THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations

Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations

NORSE: erdafitinib and cetrelimab in metastatic urothelial cancer

NORSE: erdafitinib + cetrelimab in mUC with FGFR alterations

THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab

Safety and efficacy of the erdafitinib intravesical delivery system: Phase 1: first-in-human study

European Association of Urology

#ESMO21 Highlights on erdafitinib in adv. urothelial cancer with FGFRa alterations: The NORSE study

European Society for Medical Oncology (ESMO)

discovery of KIN-3248, a pan-FGFR inhibitor

Webinar: First-in Human-Studies of FGFR Inhibitor KIN-3248 and RAF Inhibitor KIN-2787

Cholangiocarcinoma Foundation

Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations

Advances in FGFR inhibition for hepatobiliary cancer

PROOF: infigratinib as first-line therapy in patients with advanced CCA

Discussion on Trial Investigating Erdafitinib in Patients With Urothelial Cancer

Targeted Oncology

BLC2001: erdafitinib for the treatment of metastatic urothelial carcinoma

Erdafitinib and enfortumab vedotin in pretreated FGFR2/3-mutant bladder cancer

FGFR screening - the pathologist perspective

European Association of Urology

Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?

An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma